Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2003-04-01
- Last Posted Date
- 2006-09-12
- Lead Sponsor
- Biogen
- Target Recruit Count
- 400
- Registration Number
- NCT00057343
- Locations
- 🇺🇸
Research Site, Wausau, Wisconsin, United States
🇺🇸Biogen Idec Incorporated, San Diego, California, United States
Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease
- Conditions
- Crohn's Disease
- First Posted Date
- 2003-03-06
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 60
- Registration Number
- NCT00055536
- Locations
- 🇺🇸
Digestive Disease Associates, Gainesville, Florida, United States
🇺🇸Borland Groover Clinic, Jacksonville, Florida, United States
🇺🇸Atlanta Gastroenterology Associates, Atlanta, Georgia, United States
Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease
- Conditions
- Crohn's Disease
- First Posted Date
- 2003-02-28
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 30
- Registration Number
- NCT00055367
- Locations
- 🇺🇸
Cedars-Sinai IBD Center, Los Angeles, California, United States
🇺🇸Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸Miami Research Associates, Miami, Florida, United States
Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Drug: IDEC-114
- First Posted Date
- 2002-11-05
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 90
- Registration Number
- NCT00048555
- Locations
- 🇺🇸
Research site, Charlottesville, Virginia, United States
Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2002-10-02
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 70
- Registration Number
- NCT00046488
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
- Conditions
- Crohn's Disease
- First Posted Date
- 2002-04-04
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Biogen
- Registration Number
- NCT00032786
Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
- Conditions
- Crohn's Disease
- First Posted Date
- 2002-04-04
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 905
- Registration Number
- NCT00032799
- Locations
- 🇺🇸
Elan Pharmaceuticals, San Diego, California, United States
Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
- Conditions
- GliosarcomaOligoastrocytoma, MixedGlioblastoma MultiformeAnaplastic Astrocytoma
- First Posted Date
- 2002-02-22
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Biogen
- Target Recruit Count
- 12
- Registration Number
- NCT00031083
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Arizona at Tucson, Tucson, Arizona, United States
🇺🇸University of Colorado Health Sciences Center, Denver, Colorado, United States
Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: Placebo
- First Posted Date
- 2002-02-18
- Last Posted Date
- 2009-06-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1200
- Registration Number
- NCT00030966
- Locations
- 🇺🇸
University of Alabama-Birmingham, Department of Neurology, Birmingham, Alabama, United States
🇺🇸Phoenix Neurological Associates, Ltd., Phoenix, Arizona, United States
🇺🇸University of Arkansas For Medical Sciences, Little Rock, Arkansas, United States
Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: Placebo
- First Posted Date
- 2001-12-03
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 900
- Registration Number
- NCT00027300
- Locations
- 🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸East Bay Region Associates in Neurology, Berkeley, California, United States
🇺🇸UC Davis School of Medicine, Department of Neurology, Davis, California, United States